AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively.
Firstly, in vitro, AS2863619 is a potent Foxp3 inducer in Tconv cells. AS2863619 can generate Foxp3+ T cells from naïve Foxp3−CD4+ Tconv cells in a dose-dependent fashion. Similarly, AS2863619 treatment induces Foxp3 in CD8+ Tconv cells as well. Furthermore, although TCR stimulation per se elicits the expression at a low-level, AS2863619 substantially enhances FOXP3 expression in human CD4+ and CD8+ Tconv cells in the peripheral blood.
This compound induces Foxp3 expression in vitro without antigen-presenting cells (APCs). The induction is TGF-β independent and IL-2 dependent and requires TCR stimulation. It enables the conversion of antigen-specific Tconv cells into Foxp3+ suppressive T cells without TGF-β.
Moreover, in mouse CD4+ T cells, AS2863619 (1 μM; 22 hours) suppresses serine phosphorylation of the PSP motif of STAT5 to ~40%, enhancing tyrosine phosphorylation in the C-terminal domain to ~160% of control-treated samples.
Nextly, in vivo, To determine whether AS is able to induce Foxp3 in vivo in Tconv cells in an antigen-specific manner.
In DO11.10 TCR transgenic mice on the RAG2-deficient background, AS2863619 (orally administration; 30mg/kg) attains a serum concentration equivalent to an in vitro Foxp3-inducing dose, in addition, it does not cause discernible toxicity in mouse. In contrast, in RAG2-sufficient DO11.10 mice, AS2863619 specifically generates KJ 1.26+ Foxp3+ T cells, it inhibits the activation of KJ 1.26+ rather than KJ 1.26– Foxp3– Tconv cells.
After sensitization with 2,4-dinitrofluorobenzene (DNFB), AS2863619 (30 mg/kg; oral administration; daily; for 2 weeks; mice) dampen the degree of the secondary response, with milder infiltration of inflammatory cells into the skin and decreases ratios of interferon-γ+ (IFN-γ+) cells in a skin contact hypersensitivity model, when compared with vehicle-treated control mice. Treg depletion before the elicitation of the secondary response abolishes AS2863619-induced suppression.AS2863619 specifically increases KLRG1+ Foxp3+ T cells in DNFB-sensitized mice.
In conclusion, AS2863619, as a potent CDK8 and CDK19 inhibitor, has the potential for the treatment of various immunological diseases.